(Alliance News) - Syncona Ltd on Monday noted recent announcements from portfolio company Autolus Therapeutics PLC with positive new data on its cancer treatments.
This included new phase 1 trial data on its AUTO1 therapy as a treatment for patients with acute lymphoblastic leukemia. AUTO1 is a CAR T cell therapy, meaning it reprograms a patient's own immune cells to fight cancer.
Data from the AUTO1 phase 1 trials was posted on Saturday and is the basis of Autolu's decision to move forward and begin a pivotal programme in the first half of 2020 in adults with acute lymphoblastic leukemia.
On Sunday, Autolus also announced new data on its AUTO3 therapy in paediatric patients with relapsed and refractory diffuse large B-cell lymphoma, a type of blood cancer. Preliminary data on AUTO3 shows its safety and feasibility and induc3ed a completes response in 9 of the 10 patients studied, with overall survival at 100% after 12 months.
Shares in Syncona were up 1.3% at 221.00 pence in London on Monday morning.
Arix Bioscience PLC also noted the announcements from Autolus on Monday, as Autolus is its portfolio company as well. Shares in Arix were up 4.8% at 109.50p.
By Anna Farley; annafarley@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
